Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
Portfolio Pulse from Benzinga Newsdesk
Altimmune has corrected its previous release regarding the reduction of visceral and subcutaneous adipose tissue in a Phase 2 study. The visceral adipose tissue reduction at week 48 is now reported as 28.3%, up from 25.6%, while subcutaneous adipose tissue reduction is revised to 19.5% from 20.1%.
September 10, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune has revised its Phase 2 study results, increasing the reported reduction in visceral adipose tissue to 28.3% and adjusting subcutaneous adipose tissue reduction to 19.5%. This correction may positively influence investor perception of the company's clinical progress.
The correction in the study results shows a more significant reduction in visceral adipose tissue than previously reported, which could be seen as a positive development in the clinical trial's efficacy. This may enhance investor confidence in Altimmune's product pipeline, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100